Paper40980971
Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.
Henney AE and 5 others. Liver Int, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Papers, record 40980971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40980971
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Liraglutide | Major topic |
| Glucagon-Like Peptide-1 Receptor Agonists | Major topic |
| Hypoglycemic Agents | Major topic |
| Humans | |
| Glucagon-Like Peptides | |
| Male | |
| Female | |
| Middle Aged | |
| Tirzepatide | |
| Aged | |
| Dipeptidyl-Peptidase IV Inhibitors | |
| Gastric Inhibitory Polypeptide | |
| Glucagon-Like Peptide 1 | |
| Incretins | |
| Semaglutide |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34956080 | Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34956080 | PubMed |
| 2 | 38856224 | Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38856224 | PubMed |
| 3 | 38429161 | Current status and future trends of the global burden of MASLD. | Trends Endocrinol Metab | 2024 | https://conductscience.org/library/papers/38429161 | PubMed |
| 4 | 28950422 | Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/28950422 | PubMed |
| 5 | 33667417 | Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33667417 | PubMed |
| 6 | 35468322 | Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. | Lancet Diabetes Endocrinol | 2022 | https://conductscience.org/library/papers/35468322 | PubMed |
| 7 | 36934740 | Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. | Lancet Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36934740 | PubMed |
| 8 | 37193038 | A global federated real-world data and analytics platform for research. | JAMIA Open | 2023 | https://conductscience.org/library/papers/37193038 | PubMed |
| 9 | 19054785 | Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers. | Alcohol Alcohol | 2009 | https://conductscience.org/library/papers/19054785 | PubMed |
| 10 | 31591592 | Avoidable flaws in observational analyses: an application to statins and cancer. | Nat Med | 2019 | https://conductscience.org/library/papers/31591592 | PubMed |
| 11 | 38085855 | Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study. | Hepatology | 2024 | https://conductscience.org/library/papers/38085855 | PubMed |
| 12 | 34170647 | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34170647 | PubMed |
| 13 | 38498331 | Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes. | Diabetes Care | 2024 | https://conductscience.org/library/papers/38498331 | PubMed |
| 14 | 38253482 | Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. | Gut | 2024 | https://conductscience.org/library/papers/38253482 | PubMed |
| 15 | 40980971 | Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. | Liver Int | 2025 | https://conductscience.org/library/papers/40980971 | PubMed |
| 16 | 26394161 | Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | J Hepatol | 2016 | https://conductscience.org/library/papers/26394161 | PubMed |
| 17 | 28035202 | Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. | Gastroenterol Hepatol (N Y) | 2016 | https://conductscience.org/library/papers/28035202 | PubMed |
| 18 | 40015951 | Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. | Gut | 2025 | https://conductscience.org/library/papers/40015951 | PubMed |
| 19 | 38293684 | Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. | JHEP Rep | 2024 | https://conductscience.org/library/papers/38293684 | PubMed |
| 20 | 37717295 | Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. | Diabetes Metab Syndr | 2023 | https://conductscience.org/library/papers/37717295 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42689015 | Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies. | eGastroenterology | 2026 | https://conductscience.org/library/papers/42689015 | PubMed |
| 42517598 | Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42517598 | PubMed |
| 42338974 | The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities. | Eur Cardiol | 2026 | https://conductscience.org/library/papers/42338974 | PubMed |
| 40980971 | Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. | Liver Int | 2025 | https://conductscience.org/library/papers/40980971 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40980971
GET https://conductscience.org/api/papers/v1/40980971/references?page=2